secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-08-18T11:01:23+00:00
Accession:  0001437749-26-028250
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex partners with US CDMO for diabetes gene therapy manufacturing scale-up
------------------------------------------------------------------------------

- On Aug 18, 2026, Genprex entered a development/manufacturing agreement with a leading US-based CDMO.
- Agreement transitions AAV-based diabetes candidate from research-grade to clinical/commercial cGMP production.
- CDMO will supply drug product for IND-enabling preclinical studies and future clinical trials.
- Program targets T1D and T2D by delivering Pdx1 and MafA genes via AAV; also exploring non-viral LNP approach.
- Manufacturing roadmap includes process optimization, scale-up, analytical qualification, and GMP compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/0001437749-26-028250-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926028250/gnpx20260817_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-028250

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer